Why Nurix Therapeutics, Inc.’s (NRIX) Stock Is Down 6.76%
As of Monday, July 13, Nurix Therapeutics, Inc.’s NRIX share price has dipped by 6.76%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Commentary & Analysis
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or Nurix Therapeutics, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or Nurix Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Why Nurix Therapeutics, Inc.’s (NRIX) Stock Is Down 5.10%
As of Friday, July 10, Nurix Therapeutics, Inc.’s NRIX share price has dipped by 5.10%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
What You Need to Know About Nurix Therapeutics, Inc.'s Q3 Earnings
Nurix Therapeutics, Inc.'s fiscal Q3 earnings report was released on Thursday, July 09. Let's dive in to see if (NRIX) missed or beat analyst's expectations.Tudor Pop
Which Is a Better Investment, Nurix Therapeutics, Inc. or Viridian Therapeutics, Inc. Stock?
Learn more about whether Nurix Therapeutics, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Financial Summary
| Share Statistics | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,407.7 | $252.6 | 56% |
|
| Shares Out (Mil) | 111.1 | 52.3 | 64% |
|
| Institutional Ownership | 99.4% | 92.1% | 88% |
|
| Float (Mil) | 82.8 | 40.2 | 58% |
|
| Beta | 1.80 | 0.95 | 89% |
|
| Avg Daily Volume (000s) | 1,076 | 455 | 72% |
|
| Price Change (52-week) |
95.3% | 52.9% | 91% |
|
| Growth | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 36.4% | 13.6% | 92% |
|
| Net Income (5yr) | (43.7%) | (9.9%) | 8% |
|
| EPS (5yr) | (2.0%) | 16.0% | 28 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (21.8%) | (15.6%) | 30% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | $3.675 | $1.787 | ($1.439) | |
| Month Ago EPS | ($0.697) | ($2.858) | ($2.728) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 3 | 1 | 0 | |
| Three Months Ago EPS | ($0.737) | ($2.947) | ($2.864) | |
| Year/Year Chg | (556.0%) | (158.6%) | (93.4%) | |
| Financials | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $37 | $38 | 18% |
|
| Net Income (TTM) (Mil) | ($341) | ($43) | 4% |
|
| EPS (TTM) | ($3.410) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($294) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($17) | $5 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $55 | $5 | 40% |
|
| Enterprise Value (Q1) (Mil) | $2,008 | $180 | 49% |
|
| Valuation | NRIX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.98 | 2.56 | 82% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (827.3%) | 63.8% | 0% |
|
| Net Margin | (928.4%) | (67.3%) | 0% |
|
| ROA | (60.6%) | (49.8%) | 10% |
|
| ROE | (80.3%) | (55.5%) | 11% |
|
| Liabilities to Assets | 24.8% | 30.3% | 17% |
|
| F-Score | 1 | 3 | 1% |
|
Nurix Therapeutics, Inc. did not pass any screens on 7/31/2026.
